Target intelligence / Profile preview

Solute carrier family 2, facilitated glucose transporter member 3 (SLC2A3 (GLUT3))

Target
SLC2A3 (GLUT3)
Molecular classification
Transporter, Membrane protein, Glucose transporter
01

Overview

Solute carrier family 2, facilitated glucose transporter member 3 (SLC2A3), also known as glucose transporter type 3 (GLUT3), is a high-affinity glucose transporter primarily responsible for glucose uptake in neurons, but also expressed in other tissues with intense glucose demands, such as testis, placenta, certain immune cells, and various cancers[1][3][5]. It enables efficient cellular glucose influx even at low extracellular concentrations, reflecting its critical role in tissues with high and fluctuating energy requirements. SLC2A3 has higher transport capacity and affinity for glucose than most other GLUT family members, making it indispensable for normal brain function[3][5]. Aberrant SLC2A3 expression is implicated in diverse disease processes, including neurodevelopmental disorders and several cancer types, where it supports tumor growth and therapy resistance by enhancing glycolysis. It is considered a potential diagnostic, prognostic, and therapeutic target in oncology and neurology[2][4][6].

Other names
Glucose transporter type 3, brainGLUT3GLUT-3Solute carrier family 2 member 3Glucose transporter type 3SLC2A3
02

Mechanism of action

Inhibitors: Block glucose uptake in SLC2A3-expressing cells, limiting energy supply especially in cancer and highly metabolic cells. Indirect regulation (e.g., via miR-129-5p axis or compounds like curcumin): modulation of SLC2A3 expression may alter glycolytic metabolism and cell survival in targeted cells.

03

Biological functions

Glucose transport across plasma membranesFacilitation of glucose utilization in neuronsRegulation of neuronal energy metabolismInvolvement in glycolysis and HIF-1 signaling pathwayContribution to immune response (e.g., PD-L1 regulation, immune cell infiltration)
04

Disease associations

Cancer (upregulated in several cancers: colorectal cancer, head and neck squamous cell carcinoma, cholangiocarcinoma, stomach adenocarcinoma, etc.)Prognostic marker in cancer (e.g., poor prognosis marker in colorectal cancer and head and neck carcinoma)Neurodevelopmental and neurocognitive disorders (e.g., risk factor for ADHD, dyslexia due to neuronal glucose deficits)Possibly involved in metabolic disorders
05

Safety considerations

Possible risk of hypoglycemia or neuronal dysfunction if non-cancerous neuronal glucose transport is inhibited, due to its central role in neuronal glucose supplyChallenges in selectively targeting cancer cells without affecting normal neuronal tissuePotential impact on embryonic and reproductive tissues with high SLC2A3 expression
06

Interacting drugs

No approved drugs currently known to directly target SLC2A3/GLUT3 in clinical use

4 more in the full profile.

07

Biomarkers

SLC2A3 expression (mRNA/protein) as a prognostic biomarker (e.g., CRC, HNSCC)SLC2A3 expression correlates with tumor-infiltrating T lymphocyte density (potential biomarker for immunotherapy stratification)

Beyond the preview

Go deeper on Solute carrier family 2, facilitated glucose transporter member 3 (SLC2A3 (GLUT3)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solute carrier family 2, facilitated glucose transporter member 3 (SLC2A3 (GLUT3)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call